Identifying the JAK2V617F mutation has improved understanding of what causes overproduction of red blood cells, platelets, ...

PV, MANIFEST-2, and other relevant trials and how these studies help advance the management of myeloproliferative neoplasms ...

意义未明的克隆性造血（CHIP）是近年来发现的一种新型非传统心血管疾病危险因素，携带CHIP突变会使冠心病的发病风险增加约2倍。然而，CHIP基因中的JAK2 V617F突变虽然较为少见，却能增加10倍以上的冠心病风险。

近日，哈尔滨医科大学附属第二医院（简称“哈医大二院”）心血管病医院院长、心内科主任于波教授和贾海波教授团队，在心血管领域顶级期刊European Heart Journal 《欧洲心脏杂志》在线发表了题为“Plaque erosion risk and JAK2 V617F variant”的研究论文。该研究首次证实，JAK2 ...

In a randomized phase 3 trial, the combination of the BET inhibitor pelabresib with the JAK inhibitor ruxolitinib resulted in a significantly higher spleen volume reduction from baseline versus ...

研究人员在 JAK 2-V617F 小鼠模型中研究 Socs 2 对 pegIFNα 治疗 MPN 的影响，发现靶向 SOCS 2 可增效。

A panelist discusses how advances in JAK2 V617F and other molecular monitoring have enhanced their ability to assess polycythemia vera (PV) disease progression and guide initial treatment decisions by ...

COMFORT-II was a multicenter, open-label, phase 3 study comparing the safety and efficacy of ruxolitinib with that of BAT in MF. The trial population included patients diagnosed with primary MF ...